Tumor-bearing experimental animals are essential for preclinical cancer drug development.
A broad range of tumor models is available, with the simplest and most widely used …

Abstract Context Randomized controlled trials (RCTs) have shown that addition of docetaxel
or androgen receptor axis–targeted therapy (ARAT) to androgen deprivation therapy (ADT) …

Given the important roles of miRNA in post-transcriptional regulation and its implications for
cancer, characterization of miRNA facilitates us to uncover molecular mechanisms …

Background Estrogens suppress tumor growth in prostate cancer which progresses despite
anorchid serum androgen levels, termed castration resistant prostate cancers (CRPC) …

BACKGROUND: Treatment of high‐risk localized prostate cancer remains inadequate. The
authors performed a phase 2 multicenter trial of neoadjuvant docetaxel plus bevacizumab …

Abstract Background The Veterans Affairs Cooperative Studies Program study# 553 was
designed to evaluate the efficacy of adjuvant chemotherapy added to the standard of care …

Background: The low probability of curing high-risk prostate cancer (PC) with local therapy
suggests the need to study modality of therapeutic approaches. To this end, a prospective …

In our previous studies using human LNCaP xenografts and TRAMP (transgenic
adenocarcinoma of mouse prostate) mice, androgen deprivation therapy (ADT) resulted in a …

Docetaxel (DTX) is used for the treatment of advanced hormone refractory prostate cancer.
Connexin 43 (Cx43) is a tumor suppressor gene, and transfection of the Cx43 gene …

Chemotherapy with docetaxel remains the effective therapy to suppress castration resistant
prostate cancer (CRPC) in some patients. However, most chemotherapy with docetaxel …